Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...
WIB_icon

No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome

Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...
WIB_icon

Observation Versus Immunoglobulin Therapy in Children With Chronic ITP

Compared with observation, treatment with intravenous immunoglobulin (IVIg) did not prevent the risk of developing chronic immune thrombocytopenia purpura (ITP) in children newly diagnosed...
WIB_icon

Treating MPNs With JAK1/2 Inhibitors Increases Risks for B-Cell Lymphomas

JAK1/2 inhibitors have been used as standard and experimental treatment of myeloproliferative neoplasms (MPNs) for years, but according to research published in Blood, their...

Could Cord Blood Transplantation Cure Refractory Severe Aplastic Anemia?

In children and young adults with refractory severe aplastic anemia (SAA) without matched, unrelated donors, cord blood transplantation was associated with low rates of...

Are Strict Eligibility Criteria Keeping Patients From Clinical Trial Participation?

Eligibility criteria for clinical trials of leukemia therapies may be overly restrictive, limiting trial results’ applicability to real-world clinical practice and leading to unbalanced...
WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...
WIB_icon

Children With Ambiguous Leukemia Fare Better With Lymphoid-Directed Treatment

While most patients with acute leukemia have disease with a lymphoid or myeloid linage, 2 to 5 percent have “acute leukemia of ambiguous lineage”...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.